|
1
|
Thorkildsen J, Taksdal I, Bjerkehagen B,
Haugland HK, Børge Johannesen T, Viset T, Norum OJ, Bruland Ø and
Zaikova O: Chondrosarcoma in Norway 1990–2013; an epidemiological
and prognostic observational study of a complete national cohort.
Acta Oncol. 58:273–282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gazendam A, Popovic S, Parasu N and Ghert
M: Chondrosarcoma: A clinical review. J Clin Med. 12:25062023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
den Hollander D, Fiore M, Martin-Broto J,
Kasper B, Casado Herraez A, Kulis D, Nixon I, Sodergren SC, Eichler
M, van Houdt WJ, et al: Incorporating the patient voice in sarcoma
research: How can we assess health-related quality of life in this
heterogeneous group of patients? A study protocol. Cancers (Basel).
13:12020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lechler P, Renkawitz T, Campean V,
Balakrishnan S, Tingart M, Grifka J and Schaumburger J: The
antiapoptotic gene survivin is highly expressed in human
chondrosarcoma and promotes drug resistance in chondrosarcoma cells
in vitro. BMC Cancer. 11:1202011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weinschenk RC, Wang WL and Lewis VO:
Chondrosarcoma. J Am Acad Orthop Surg. 29:553–562. 2021.PubMed/NCBI
|
|
6
|
Li J, Shen F, Guan C, Wang W, Sun X, Fu X,
Huang M, Jin J and Huang Z: Activation of Nrf2 protects against
triptolide-induced hepatotoxicity. PLoS One. 9:e1006852014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu H, Huang G, Wang H, Li X, Wang X, Feng
Y, Tan B and Chen T: Inhibition effect of triptolide on human
epithelial ovarian cancer via adjusting cellular immunity and
angiogenesis. Oncol Rep. 39:1191–1196. 2018.PubMed/NCBI
|
|
8
|
Sun YY, Xiao L, Wang D, Ji YC, Yang YP, Ma
R and Chen XH: Triptolide inhibits viability and induces apoptosis
in liver cancer cells through activation of the tumor suppressor
gene p53. Int J Oncol. 50:847–852. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu H, Shen M, Zhao D, Ru D, Duan Y, Ding
C and Li H: The effect of triptolide-loaded exosomes on the
proliferation and apoptosis of human ovarian cancer SKOV3 cells.
Biomed Res Int. 2019:25958012019.PubMed/NCBI
|
|
10
|
Tong X, Jiang P, Li Y, Guo L, Zhang HM,
Zhang BK and Yan M: Combined treatment with triptolide and tyrosine
kinase inhibitors synergistically enhances apoptosis in non-small
cell lung cancer H1975 cells but Not H1299 cells through EGFR/Akt
pathway. Chem Pharm Bull (Tokyo). 67:864–781. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie M, Wu J, Ji L, Jiang X, Zhang J, Ge M
and Cai X: Development of triptolide Self-Microemulsifying drug
delivery system and its anti-tumor effect on gastric cancer
Xenografts. Front Oncol. 9:9782019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng W, Wang C, Ding R, Huang Y, Li Y and
Lu Y: Triptolide-loaded nanoparticles targeting breast cancer in
vivo with reduced toxicity. Int J Pharm. 572:1187212019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cai J, Yi M, Tan Y, Li X, Li G, Zeng Z,
Xiong W and Xiang B: Natural product triptolide induces
GSDME-mediated pyroptosis in head and neck cancer through
suppressing mitochondrial hexokinase-II. J Exp Clin Cancer Res.
40:1902021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong X, Chen Y and Wu Y: Absorption and
metabolism characteristics of triptolide as determined by a
sensitive and reliable LC-MS/MS method. Molecules. 20:8928–8940.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Propper D, Borazanci D, O'Dwyer PJ, Von
Hoff D, Hartlebury J, Antal CE, Evan GI, Han HY, Downes M, Evans R,
et al: Phase II open label trial of Minnelide™ in patients with
chemotherapy refractory metastatic pancreatic cancer [abstract].
Proceedings of the American Association for Cancer Research Annual
Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited
Abstracts); 2024 Apr 5–10; San Diego, CA Philadelphia (PA): AACR.
Cancer Res 84 (7_Suppl): Abstract nr CT218. 2024
|
|
16
|
Propper D, Borazanci E, O'Dwyer PJ, Von
Hoff D, Hartlebury J, Antal CE, Evan GI, Han HY, Downes M, Evans R,
et al: Abstract CT218: Phase II open label trial of Minnelide™ in
patients with chemotherapy refractory metastatic pancreatic cancer.
Cancer Res 84 (7_Supplement). CT2182024. View Article : Google Scholar
|
|
17
|
Mu L, Wu P, Zhang Y, Li S, Yang R and Wang
S: Development of a novel oral complex lipid emulsion containing
triptolide for targeting pancreatic cancer. Pharm Dev Technol.
27:881–891. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan W, Huang J, Hou S, Li H, Bie L, Chen
B, Li G, Zhou Y and Chen X: The antigastric cancer effect of
triptolide is associated with H19/NF-κB/FLIP axis. Front Pharmacol.
13:9185882022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Z, Yeung S, Yang S, Huang Y and Sum
Chow MS: Chemosensitizing effect and efficacy of wilforlide A in
combination with docetaxel in drug-resistant prostate cancer. In
vivo. 36:2020–2031. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Q, Zhai X and Lv Y: A bibliometric
analysis of triptolide and the recent advances in treating
non-small cell lung cancer. Front Pharmacol. 13:8787262022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia Y, Shen S and Verma IM: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song M, Wang X, Luo Y, Liu Z, Tan W, Ye P,
Fu Z, Lu F, Xiang W, Tang L, et al: Cantharidin suppresses gastric
cancer cell migration/invasion by inhibiting the PI3K/Akt signaling
pathway via CCAT1. Chem Biol Interact. 317:1089392020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song CY, Chang SLY, Lin CY, Tsai CH, Yang
SY, Fong YC, Huang YW, Wang SW, Chen WC and Tang CH:
Visfatin-induced inhibition of miR-1264 facilitates PDGF-C
synthesis in chondrosarcoma cells and enhances endothelial
progenitor cell angiogenesis. Cells. 11:34702022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Truong DD, Lamhamedi-Cherradi SE and
Ludwig JA: Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ
pathways in primary bone cancer. J Bone Oncol. 33:1004192022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu M, Ying J, Lin C, Wang Y, Huang K,
Zhou Y and Teng H: Baicalin induces apoptotic death of human
chondrosarcoma cells through mitochondrial dysfunction and
downregulation of the PI3K/Akt/mTOR pathway. Planta Med.
85:360–369. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saji M, Kim CS, Wang C, Zhang X, Khanal T,
Coombes K, La Perle K, Cheng SY, Tsichlis PN and Ringel MD: Akt
isoform-specific effects on thyroid cancer development and
progression in a murine thyroid cancer model. Sci Rep.
10:183162020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pappa T, Ahmadi S, Marqusee E, Johnson HL,
Nehs MA, Cho NL, Barletta JA, Lorch JH, Doherty GM, Lindeman NI, et
al: Oncogenic mutations in PI3K/AKT/mTOR pathway effectors
associate with worse prognosis in BRAFV600E-Driven papillary
thyroid cancer patients. Clin Cancer Res. 27:4256–4264. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Micaily I, Roche M, Ibrahim MY,
Martinez-Outschoorn U and Mallick AB: Metabolic pathways and
targets in chondrosarcoma. Front Oncol. 11:7722632021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsieh TH, Hsu CY, Tsai CF, Long CY, Wu CH,
Wu DC, Lee JN, Chang WC and Tsai EM: HDAC inhibitors target HDAC5,
upregulate microRNA-125a-5p, and induce apoptosis in breast cancer
cells. Mol Ther. 23:656–666. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qiang S, Ma XN, Wang HW and Lv SC: Scapula
chondrosarcoma: A case report. Medicine (Baltimore). 98:e153882019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slater R, Oblak M, Wright T and Matsuyama
A: Preserved limb function following subtotal iliopsoas muscle and
femoral nerve resection in a dog with low grade intramuscular
chondrosarcoma. Can Vet J. 60:490–494. 2019.PubMed/NCBI
|
|
33
|
Tzeng HE, Tang CH, Wu SH, Chen HT, Fong
YC, Lu YC, Chen WC, Huang HD, Lin CY and Wang SW: CCN6-mediated
MMP-9 activation enhances metastatic potential of human
chondrosarcoma. Cell Death Dis. 9:9552018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu JF, Huang YL, Yang WH, Chang CS and
Tang CH: 1-benzyl-2-phenylbenzimidazole (BPB), a benzimidazole
derivative, induces cell apoptosis in human chondrosarcoma through
intrinsic and extrinsic pathways. Int J Mol Sci. 13:16472–1688.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pei S, Yang X, Wang H, Zhang H, Zhou B,
Zhang D and Lin D: Plantamajoside, a potential anti-tumor herbal
medicine inhibits breast cancer growth and pulmonary metastasis by
decreasing the activity of matrix metalloproteinase-9 and −2. BMC
Cancer. 15:9652015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang M, Chen B and Chai L: Triptolide
suppresses the proliferation and induces the apoptosis of
nasopharyngeal carcinoma cells via the PI3K/Akt pathway. Oncol
Lett. 17:1372–1378. 2019.PubMed/NCBI
|
|
37
|
Wang S, Guo Q, Xu R, Lin P, Deng G and Xia
X: Combination of ferroptosis and pyroptosis dual induction by
triptolide nano-MOFs for immunotherapy of melanoma. J
Nanobiotechnology. 21:3832023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tian Q, Zhang P, Wang Y, Si Y, Yin D,
Weber CR, Fishel ML, Pollok KE, Qiu B, Xiao F and Chong AS: A novel
triptolide analog downregulates NF-κB and induces mitochondrial
apoptosis pathways in human pancreatic cancer. ELife.
12:e858622023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu L, Gao M, Jiang H, Zhuang L, Jiang Y,
Xie S, Zhang H, Wang Q and Chen Q: Triptolide inhibits epithelial
ovarian tumor growth by blocking the hedgehog/Gli pathway. Aging
(Albany NY). 15:11131–11151. 2023.PubMed/NCBI
|
|
40
|
Fang K, Sun Y, Yang J, Hu X, Chen M, Li R,
Yang X, Fan T, Wu J, Tong X, et al: A dual stimuli-responsive
Nanoplatform Loaded PtIV-Triptolide prodrug for achieving
synergistic therapy toward breast cancer. Adv Healthc Mater.
12:e23013282023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li L, Wang C, Qiu Z, Deng D, Chen X, Wang
Q, Meng Y, Zhang B, Zheng G and Hu J: Triptolide inhibits
intrahepatic cholangiocarcinoma growth by suppressing glycolysis
via the AKT/mTOR pathway. Phytomedicine. 109:1545752023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu X, Chen S, Huang K and Lin G:
Triptolide promotes ferroptosis by suppressing Nrf2 to overcome
leukemia cell resistance to doxorubicin. Mol Med Rep. 27:172023.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang X, Gao H, Wei D, Pei X, Zhang Y,
Wang J, Ding D, Chang J and Wu X: ROS responsive nanoparticles
encapsulated with natural medicine remodel autophagy homeostasis in
breast cancer. ACS Appl Mater Interfaces. 15:29827–29840. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yalikong A, Li XQ, Zhou PH, Qi ZP, Li B,
Cai SL and Zhong YS: A triptolide loaded HER2-targeted nano-drug
delivery system significantly suppressed the proliferation of
HER2-positive and BRAF mutant colon cancer. Int J Nanomedicine.
16:2323–2335. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Luo Y, Li J, Hu Y, Gao F, Pak-Heng Leung
G, Geng F, Fu C and Zhang J: Injectable thermo-responsive
nano-hydrogel loading triptolide for the anti-breast cancer
enhancement via localized treatment based on ‘Two Strikes’ effects.
Acta Pharm Sin B. 10:2227–2245. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Long C, Guo W, Zhou H, Wang J, Wang H and
Sun X: Triptolide decreases expression of latency-associated
nuclear antigen 1 and reduces viral titers in Kaposi's
sarcoma-associated and Herpesvirus-related primary effusion
lymphoma cells. Int J Oncol. 48:1519–1530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Grzegorzewska AE, Frankiewicz D,
Bręborowicz D, Matławska I and Bylka W: Disseminated cutaneous
Kaposi sarcoma in a patient receiving triptolide/tripdiolide for
rheumatoid arthritis. Med Sci Monit. 18:CS67–CS71. 2012.PubMed/NCBI
|
|
48
|
Colotta F, Allavena P, Sica A, Garlanda C
and Mantovani A: Cancer-related inflammation, the seventh hallmark
of cancer: Links to genetic instability. Carcinogenesis.
30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huo L, Wang B, Zheng M, Zhang Y, Xu J,
Yang G and Guan Q: miR-128-3p inhibits glioma cell proliferation
and differentiation by targeting NPTX1 through IRS-1/PI3K/AKT
signaling pathway. Exp Ther Med. 17:2921–2930. 2019.PubMed/NCBI
|
|
51
|
Mo M, Peng F, Wang L, Peng L, Lan G and Yu
S: Roles of mitochondrial transcription factor A and
microRNA-590-3p in the development of bladder cancer. Oncol Lett.
6:617–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhuang S, Li L, Zang Y, Li G and Wang F:
RRM2 elicits the metastatic potential of breast cancer cells by
regulating cell invasion, migration and VEGF expression via the
PI3K/AKT signaling. Oncol Lett. 19:3349–3355. 2020.PubMed/NCBI
|
|
53
|
Chu E, Mychasiuk R..Hibbs ML and Semple
BD: Dysregulated phosphoinositide 3-kinase signaling in microglia:
Shaping chronic neuroinflammation. J Neuroinflammation. 18:2762021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Weichhart T and Säemann MD: The
PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic
applications. Ann Rheum Dis. 67 (Suppl 3):iii70–iii74. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ni W, Fang Y, Tong L, Tong Z, Yi F, Qiu J,
Wang R and Tong X: Girdin regulates the migration and invasion of
glioma cells via the PI3K-Akt signaling pathway. Mol Med Rep.
12:5086–5092. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Filippova EV, Zemaitaitis B, Aung T, Wolfe
AJ and Anderson WF: Structural basis for DNA recognition by the
two-component response regulator RcsB. mBio. 9:e01993–17. 2028.
|
|
57
|
Chen C, Tian A, Zhou H, Zhang X, Liu Z and
Ma X: Upregulation of miR-211 promotes chondrosarcoma development
via targeting tumor suppressor VHL. Onco Targets Ther.
13:2935–2943. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hsieh T, Hsu C, Tsai C, Long C, Chai C,
Hou M, Lee J, Wu D, Wang S and Tsai E: miR-125a-5p is a prognostic
biomarker that targets HDAC4 to suppress breast tumorigenesis.
Oncotarget. 6:494–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pan L, Qin Z, Zhou Q, Zheng P, Li H, Zhou
X and Qin Y: Unlocking the therapeutic potential: Harnessing
miR-125a-5p to enhance autophagy and apoptosis in pancreatic cancer
through targeting STAT3. J Cancer. 15:4955–4968. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Guo M, Su F, Chen Y and Su B: Ectopic
circSTK39 expression ameliorates hydrogen peroxide-induced human
lens epithelial cell apoptosis and oxidative stress through the
miR-125a-5p/ERCC6 pathway. Curr Eye Res. 48:278–288. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chu M, Fan Y, Wu L, Ma X, Sao J, Yao Y,
Zhuang W and Zhang C: Knockdown of lncRNA BDNF-AS inhibited the
progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2
axis. Immun Ageing. 19:32022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xueya Z, Yamei L, Sha C, Dan C, Hong S,
Xingyu Y and Weiwei C: Exosomal encapsulation of miR-125a-5p
inhibited trophoblast cell migration and proliferation by
regulating the expression of VEGFA in preeclampsia. Biochem Biophys
Res Commun. 525:646–653. 2020. View Article : Google Scholar : PubMed/NCBI
|
